Company intelligence / Profile preview

Pignx

Boulder, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Pignus Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation precision oncology treatments. The company specializes in the discovery and development of isoform-selective inhibitors of phosphoinositide 3-kinase alpha (PI3K alpha), a critical driver in various solid tumors. By leveraging deep expertise in structure-based drug design, Pignus aims to create therapies with improved safety profiles and greater efficacy compared to existing PI3K inhibitors. Their lead programs target specific mutations in the PIK3CA gene, which are prevalent in breast and other cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Pignx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pignx.

Explore the full profile